

Supplementary Materials

Differences in the Clinical and Molecular Profiles of Subungual Melanoma and Acral Melanoma in Asian Patients

So-Young Ahn, Go Eun Bae, Seung-Yeol Park and Min-Kyung Yeo




Figure S1. Kaplan–Meier curves showing overall survival of patients with SUM and AM stratified according to the stages. (left) All melanoma patients with SUM and AM, including in situ melanoma; (right) patients with invasive melanoma.




Figure S2. Kaplan–Meier curves showing overall survival of patients with SUM and AM stratified according to the Breslow thickness. (left) All melanoma patients with SUM and AM, including in situ melanoma; (right) patients with invasive melanoma.

Table S1. Demographic data of 42 patients with subglanular melanoma during 15 years.

Characteristics	Patients Number (%)
Age at diagnosis (mean)	55.7
Sex	
Male	20 (47.6)
Female	22 (52.4)
Tumor Location	
Upper	29 (69.0)
Lower	13 (31.0)
Size (mean, cm)	1.2 cm
Breslow Thickness	
In situ	12 (28.6)
<1 mm	12 (28.6)
1.01-2.00mm	4 (9.5)
2.01-4.00 mm	5 (11.9)
>4.00 mm	9 (21.4)
Clark Level	
1	12 (28.6)
2	11 (26.2)
3	6 (14.3)
4	5 (11.9)
5	8 (19.0)
Ulceration	
Absent	31 (73.8)
Present	11 (26.2)
Mitotic rate/mm ² (mean)	3.0/mm ²
Lymph Node Metastasis at the Time of Diagnosis	
Absent	35 (83.3)
Present	7 (16.7)
Distant Metastasis at the Time of Diagnosis	
Absent	41 (97.6)
Present	1 (2.4)
Stage Group	
0	12 (28.6)
I	11 (26.2)
II	12 (28.6)
III	6 (14.3)
IV	1 (2.4)
Chemotherapy	
Not done	30 (71.4)
Done	12 (28.6)
Radiotherapy	
Not done	39 (73.8)
Done	3 (26.2)
Immunotherapy	
Not done	31 (73.8)
Done	11 (26.2)
Trauma	
Absent	37 (88.1)
Present	5 (11.9)

Table S2. Gene lists for Oncomine Comprehensive Assay version 3 (n=170).

Small nucleotide variant and indels (Hotspot genes, n=170, from DNA)					
ABL1, ABL2, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ASXL1, ATM, ATR, AURKA, AURKB, AURKC, AXL, BAP1, BCL2, BRAF, BRCA1, BRCA2, BRD2, BRD3, BRD4, CBFB, CCND1, CCND2, CCND3, CCNE1, CDH1, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK2, CREBBP, CRKL, CSF1R, CTNNB1, DDR1, DDR2, MAP3K4, MAPK1, MAPK3, MAPK8, MCL1, MDM2, MDM4, MED12, MEN1, MET, MITE, MLH1, MPL, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NF1, NF2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NRAS, NTRK1, NTRK2, NTRK3, NUTM1, PDGFB, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PIK3CD, PIK3R1, PIK3R2, POLE, PPARG, PTCH1, PTEN, RAB35, RAD50, RAF1, RARA, RB1, RET, RHEB, RICTOR, RNF43, ROS1, RSPO1, RSPO2, RUNX1, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SRC, STK11, SYK, TET2, TMRSS2, TOP2A, TP53, TSC1, TSC2, VHL, WT1, XPO1, ZNRF3, TERT					
Copy number variation (n=47, from DNA)					
AKT1	FGFR1	MDM2	PPARG	CCND3	NTRK2
AR	FGFR2	MDM4	TERT	CDK2	NTRK3
CCND1	FGFR3	MET	AKT2	CDKN2A	PDGFRB
CCNE1	FGFR4	MYC	AKT3	CDKN2B	PIK3CB
CDK4	FLT3	MYCL	ALK	ESR1	RICTOR
CDK6	IGF1R	MYCN	AXL	FGF19	TSC1
EGFR	KIT	PDGFRA	BRAF	FGF3	TSC2
ERBB2	KRAS	PIK3CA	CCND2	NTRK1	
Fusions and splice variants (n=51 from RNA)					
ALK	FGFR1	ROS1	FLT3	NOTCH4	RAD51B
AXL	FGFR2	AKT2	JAK2	NRG1	RB1
BRAF	FGFR3	AR	KRAS	NTRK2	RELA
EGFR	NTRK1	BRCA1	MDM4	NUTM1	RSPO2
ERBB2	NTRK3	BRCA2	MET	PDGFRB	RSPO3
ERG	PDGFRA	CDKN2A	MYB	PIK3CA	TERT
ETV1	PPARG	ERBB4	MYBL1	PRKACA	
ETV4	RAF1	ESR1	NF1	PRKACB	
ETV5	RET	FGR	NOTCH1	PTEN	

Table S3. Melanoma patients enrolled in pathology archives in a single institute (CNUH) from 200 to 2022 (15 years).

Cutaneous		245	81%
Acral		151	50%
Subungual (28% of AM)		43	14%
Other Cutaneous (Superficial Spreading, Nodular, Lentigo Maligna)		94	
Mucosal		47	16%
Oral and Nasal		35	
Digestive Tract (Including Anorectal)		7	
Vulvovaginal		4	
Genitourinary (Including Penis)		1	
Ocular		10	3%
Including Conjunctiva			
Total		302	100%